Bank Julius Baer & Co. Ltd Zurich Buys 693 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Bank Julius Baer & Co. Ltd Zurich lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 14.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,403 shares of the company’s stock after buying an additional 693 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in TransMedics Group were worth $372,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Geode Capital Management LLC boosted its position in TransMedics Group by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after buying an additional 10,106 shares during the period. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after acquiring an additional 32,605 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of TransMedics Group by 9.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company’s stock worth $18,545,000 after purchasing an additional 25,739 shares during the period. Baillie Gifford & Co. grew its stake in shares of TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after purchasing an additional 34,947 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on TMDX shares. Robert W. Baird cut their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group decreased their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Finally, Oppenheimer reiterated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Down 2.1 %

TransMedics Group stock opened at $66.03 on Tuesday. The company has a market capitalization of $2.22 billion, a PE ratio of 70.25 and a beta of 2.12. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm’s fifty day moving average is $68.44 and its 200 day moving average is $96.43. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.